# High TSH levels during TSH suppression therapy in DTC postoperative patients are associated with low DIO2 expression in the thyroid and impaired thyroid hormone sensitivity

**Authors:** Jialu Wu, Juan Huang, Zhe Yan, Anqi Yuan, Yifei Song, Hui Huang

PMC · DOI: 10.3389/fendo.2025.1607927 · Frontiers in Endocrinology · 2025-10-01

## TL;DR

Some thyroid cancer patients have high TSH levels after treatment, linked to low DIO2 enzyme activity and poor thyroid hormone sensitivity.

## Contribution

Identifies DIO2 expression and thyroid hormone sensitivity as factors in poor TSH suppression therapy response in DTC patients.

## Key findings

- High TSH group showed significantly lower FT3/FT4 ratios and higher central thyroid sensitivity indices.
- Reduced DIO2 expression was observed in thyroid tissues of the High TSH group.
- TSH index predicts the efficacy of L-T4 monotherapy in DTC patients.

## Abstract

Some patients with differentiated thyroid cancer (DTC) exhibit persistently elevated TSH levels despite undergoing TSH suppression therapy after total thyroidectomy. This study aims to investigate the expression of type 2 deiodinase (DIO2) in thyroid tissues, as well as central and peripheral thyroid hormone sensitivity in these patients.

A total of 162 DTC patients who underwent total thyroidectomy and received TSH suppression therapy were enrolled. Patients were stratified into Low TSH and High TSH groups based on postoperative TSH levels. Thyroid function and thyroid hormone sensitivity indices were compared before and after treatment, and DIO2 expression in normal thyroid tissue was analyzed.

All patients showed significantly elevated FT4 levels after TSH suppression therapy. Postoperative FT3 levels in the High TSH group were lower than preoperative levels. Notably, the High TSH group exhibited significantly lower FT3/FT4 ratios and higher central thyroid sensitivity indices than the Low TSH group. Immunohistochemistry revealed reduced DIO2 expression in thyroid tissues of the High TSH group. This significant difference persisted when analysis was restricted to patients with normal FT4 levels in both groups.

DTC patients with persistently high postoperative TSH levels display lower DIO2 expression in normal thyroid tissues. These findings suggest that poor responders to TSH suppression therapy inherently exhibit impaired central and peripheral thyroid hormone sensitivity, which may be exacerbated by total thyroidectomy. TSH index shows predictive value for L-T4 monotherapy efficacy. These results highlight the need for personalized TSH suppression strategies in DTC management.

## Linked entities

- **Genes:** DIO2 (iodothyronine deiodinase 2) [NCBI Gene 1734]
- **Chemicals:** L-T4 (PubChem CID 5819), FT4 (PubChem CID 25817650), FT3 (PubChem CID 23656595), TSH (PubChem CID 1150)
- **Diseases:** differentiated thyroid cancer (MONDO:0015447), thyroid cancer (MONDO:0002108)

## Full-text entities

- **Genes:** DIO2 (iodothyronine deiodinase 2) [NCBI Gene 1734] {aka 5DII, D2, DIOII, SELENOY, SelY, TXDI2}
- **Diseases:** impaired (MESH:D060825), DTC (MESH:D013964)
- **Chemicals:** L-T4 (MESH:D013974), TSH (MESH:D013972), FT3 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12520876/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12520876/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12520876/full.md

---
Source: https://tomesphere.com/paper/PMC12520876